Management Team

Jerry Williamson

President and Chief Executive Officer

Jerry Williamson brings more than 30 years of commercial operating, business development and corporate management experience in the diagnostic and life science marketplace where he has held executive leadership roles responsible for value creation, growth and profitability. Most recently, Jerry was President and CEO of Metamark Genetics, Inc., a private molecular diagnostics company, which he joined in 2015.

Prior to Metamark, Jerry was a Partner with Flagship Ventures focused on building and developing relationships with corporate partners for the firm’s core innovation and investment activities. He was President of Global Commercial Operations for Genetix Ltd., a UK-based bioresearch imaging company that was sold to Danaher and merged with Molecular Devices where Jerry served as Vice President and General Manager. As President of Biacore, Inc., Jerry ran the North American subsidiary of this European biotech instrument supplier, where he was also responsible for post-acquisition integration into GE Healthcare. Jerry was also President of Pyrosequencing, Inc., the US subsidiary of a Swedish-led DNA sequencing platform provider.

Jerry received a BS degree in Biochemistry from the University of Vermont and holds an MBA degree from Boston University.

Stephen Lyle, MD, PhD

Vice President, Clinical Services and Laboratory Director

Prior to joining KEW, Dr. Lyle was a professor of pathology at the University of Massachusetts Medical Center and also served as lab director at Predictive Biosciences, medical director at Catalyst Oncology and laboratory site director for Ardais Corporation.

Alexei Protopopov, PhD

Executive Scientific Advisor

Dr. Protopopov joined KEW after more than two decades of cancer genetics research. During his career, he oversaw several genomic data production programs including leading IACS Cancer Genomics at MD Anderson, Belfer Center for Cancer Genomics at Dana-Farber, TCGA Genome Characterization Center at Harvard Medical School/MDACC.

Board of Directors

Tuan Ha-Ngoc

Executive Chairman

Tuan Ha-Ngoc has more than 30 years of senior leadership experience in the biotech industry. In June 2015, he was appointed executive chairman of KEW, Inc. a molecular profiling company utilizing Next Generation Sequencing technology with a mission of bringing Precision Medicine to All. From January to November 2015, Mr. Ha-Ngoc was the chairman of the Board of AVEO Pharmaceuticals, Inc., a company dedicated in the discovery and development of novel cancer medicines, having been its president and CEO since the beginning in 2002. From 1999 to 2002, he was co-founder, president and chief executive officer of deNovis, Inc., an enterprise-scale software development company for the automation of healthcare administrative functions. From 1998 to 1999, Mr. Ha-Ngoc was corporate vice president of strategic development for Wyeth, following Wyeth’s acquisition of Genetics Institute, where Mr. Ha-Ngoc served from 1984 to 1997 as executive vice president with responsibility for corporate development, commercial operations and European and Japanese operations. From 1976 to 1984, he served in various management capacities with Baxter Health Care first at their European headquarters then at their corporate offices in Deerfield, IL. He holds an M.B.A. from INSEAD and an M.A. in pharmacy from the University of Paris, France.

Raju Kucherlapati, PhD

KEW Founder, Board Member

Founder and board member of KEW, Inc. Dr. Kucherlapati currently serves as the Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School Director Emeritus, Harvard Medical School-Partners HealthCare Center for Personalized Genetic Medicine and Principal Investigator at the Genome Characterization Center. Dr. Kucherlapati also serves as a member of the Presidential Commission for the Study of Bioethical Issues, was a key contributor to the groundbreaking Human Genome Project and a contributing author of the published results.

Jerry Williamson

President and Chief Executive Officer

Jerry Williamson brings more than 30 years of commercial operating, business development and corporate management experience in the diagnostic and life science marketplace where he has held executive leadership roles responsible for value creation, growth and profitability. Most recently, Jerry was President and CEO of Metamark Genetics, Inc., a private molecular diagnostics company, which he joined in 2015.

Prior to Metamark, Jerry was a Partner with Flagship Ventures focused on building and developing relationships with corporate partners for the firm’s core innovation and investment activities. He was President of Global Commercial Operations for Genetix Ltd., a UK-based bioresearch imaging company that was sold to Danaher and merged with Molecular Devices where Jerry served as Vice President and General Manager. As President of Biacore, Inc., Jerry ran the North American subsidiary of this European biotech instrument supplier, where he was also responsible for post-acquisition integration into GE Healthcare. Jerry was also President of Pyrosequencing, Inc., the US subsidiary of a Swedish-led DNA sequencing platform provider.

Jerry received a BS degree in Biochemistry from the University of Vermont and holds an MBA degree from Boston University.

Joyce Erony

Board Member

Mrs. Erony has more than 25 years experience as a principal in investing activities, investment banking and business development. She is currently a Director of ImpoPharma, IGI Labs and Fluxion and has been a Director of Peak Surgical (acquired by Medtronic), Dow Pharmaceutical Sciences (acquired by Valeant), Atlantis Components (acquired by AstraZeneca) , and Control Delivery Systems (acquired by Psivida).

Previously, Mrs. Erony was a strategic advisor to Alcon Labs and was a Managing Director at Citigroup responsible for the Bank’s activities in specialty pharmaceuticals and medical technologies.

Valerie Friedman, MBA

Board Member

Ms. Friedman is currently a principal at a Boston-based hedge fund.

H. Robert Horvitz, PhD

Board Observer

In addition to serving as a KEW, Inc. , Dr. Horvitz is an investigator at the Howard Hughes Medical Institute and David H. Koch professor in the MIT Department of Biology. He was awarded the Nobel Prize in Physiology or Medicine in 2002.

Thomas Miller

Independent Director

Mr. Miller received his B.S. in Nuclear Engineering from the University of Massachusetts, and received his Masters of Science degree from the Harvard-MIT Program in Health Sciences and Technology. A seasoned executive in the diagnostic space, Mr. Miller previously served as Chief Executive Officer (CEO) of Siemens Healthcare’s Customer Solutions Division, responsible for an organization of 26,000 employees in over 130 countries. He also held other leadership roles during his tenure at Siemens, including serving as a member of the Group Board of Siemens Medical Solutions, as well as overseeing the company’s global MRI business. In addition, Mr. Miller has served as CEO for several other organizations, including Global Medical Operations of Carl Zeiss, Inc.; Analogic Corporation; and LightLab Imaging, a start-up he helped to establish and sell, and for whom he also served as Chairman. In April 2013, he founded GreyBird Ventures, a consultancy and investment firm, where he currently serves as director, advisor, and/or investor in six healthcare start-up companies.

Justin Simoncini

Board Member

Mr. Simoncini has over 10 years of experience in Healthcare. He is currently leading strategy and business development for Cardinal Health Specialty Solutions. Previously Mr. Simoncini held various positions in investment banking at Bank of America Merrill Lynch and RBC Capital Markets, and worked in corporate finance and strategic planning at Pfizer, Inc. He holds an MBA from Harvard Business School, a Master’s degree in Public Health from Columbia University and a Bachelor’s degree from the University of Virginia.

Scientific Advisors

Charles Fuchs, MD, MPH

Dr. Fuchs is the Yale Cancer Center Director and Physician-in-Chief at Smilow Cancer Hospital at Yale New Haven. An internationally recognized expert in gastrointestinal cancers and cancer epidemiology, Dr. Fuchs was most recently a Professor of Medicine at Harvard Medical School and Chief of the Gastrointestinal Oncology Division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.

Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health. He has written over 550 scientific publications and, most recently, served as a member of the National Cancer Institute Blue Ribbon Panel Working Group.

Jeffrey Golden, MD

Dr. Golden is the Ramzi S. Cotran Professor of Pathology at Harvard Medical School and the Chair of Pathology at the Brigham and Women’s Hospital. He is a physician-scientist whose research is focused on elucidating the molecular and cellular mechanisms underlying neurodevelopmental disorders. His administrative roles, in addition to Department Chair of Pathology, include being and Chair of the Board for the Brigham and Women’s Physician Organization and leading the Computational Pathology and Precision Medicine programs at the Brigham and Women’s Hospital. These programs are focused on methods to integrate large data sets to enhance our ability to diagnose, prognosticate, stratify patient treatments, conduct biomarker discovery, and enable actionable targeted therapy implementation.

Dr. Golden is the past president of the American Association of Neuropathologists and serves on numerous national and international committees.

H. Robert Horvitz, PhD

Board Observer

In addition to serving as a KEW, Inc. , Dr. Horvitz is an investigator at the Howard Hughes Medical Institute and David H. Koch professor in the MIT Department of Biology. He was awarded the Nobel Prize in Physiology or Medicine in 2002.

Raju Kucherlapati, PhD

KEW Founder, Board Member

Founder and board member of KEW, Inc. Dr. Kucherlapati currently serves as the Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School Director Emeritus, Harvard Medical School-Partners HealthCare Center for Personalized Genetic Medicine and Principal Investigator at the Genome Characterization Center. Dr. Kucherlapati also serves as a member of the Presidential Commission for the Study of Bioethical Issues, was a key contributor to the groundbreaking Human Genome Project and a contributing author of the published results.

Howard McLeod, PharmD

Howard McLeod, PharmD, is Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center, chair of the Department of Individualized Cancer Management and a Florida Endowed Chair in Cancer Research at the University of South Florida.

He was a professor and founding director of the UNC Institute for Pharmacogenomics and Individualized Therapy. Dr. McLeod is chair of the NHGRI eMERGE network external scientific panel and a member of the FDA committee on clinical pharmacology and the NIH NHGRI Advisory Council. Since 2002, Dr. McLeod has been vice chair for pharmacogenomics for the NCI clinical trials CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world.

He is a 1000 Talent Scholar of China and a professor at Central South University in China. Dr. McLeod has published over 500 peer reviewed articles on pharmacogenomics, applied therapeutics and clinical pharmacology, and is dedicated to integrating genetics principles into clinical practice to advance individualized medicine.

Founders

Raju Kucherlapati, PhD

KEW Founder, Board Member

Founder and board member of KEW, Inc. Dr. Kucherlapati currently serves as the Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School Director Emeritus, Harvard Medical School-Partners HealthCare Center for Personalized Genetic Medicine and Principal Investigator at the Genome Characterization Center. Dr. Kucherlapati also serves as a member of the Presidential Commission for the Study of Bioethical Issues, was a key contributor to the groundbreaking Human Genome Project and a contributing author of the published results.

Jeffrey Elton, MD

Dr. Elton is the current managing director of and global head, Predictive Health Intelligence at Accenture. He has over 20 years of experience as a global executive and consultant in the biopharmaceutical and healthcare sectors.  He was previously the global COO and strategy head of the Novartis Institutes for Biomedical Research and a partner in health care and life sciences at McKinsey & Company.

Kathy Behrens Wilsey, PhD

Prior to co-founding KEW, Inc. as CEO, Dr. Behrens Wilsey served as a managing partner of venture funds at Robertson Stephens Investments, the president and chair of the National Venture Capital Association, and a member of the President’s Council of Advisors on Science and Technology.

Call us

855.225.4068

Email

kewcustomercare@kewinc.com

Location

840 Memorial Drive, 4th Floor Cambridge, MA 02139